Testosterone Propionate

Testosterone propionate in brief

Three numbers frame testosterone propionate: how long one injection kept testosterone above normal, how the long ester behaves by comparison, and what the hormone did to muscle at the dose-response level.

Every figure is taken from the abstracts of the twenty-five papers at the end. Testosterone propionate and the other esters are named because the papers name them; no dose, schedule or cycle is given here.

What this testosterone propionate profile covers

What is testosterone propionate? The ester and the hormone

Testosterone propionate is testosterone with a three-carbon propionic acid ester on the 17-beta hydroxyl, dissolved in oil for intramuscular injection. The ester does nothing at the receptor; it delays release from the oil depot and is cleaved by esterases to free testosterone in the blood. The shorter the ester, the faster the release and the shorter the exposure, and propionate is the shortest ester in common clinical use. It was the first injectable testosterone ester, marketed in the 1930s, and it survives today in mixed-ester preparations and in a topical form.

The two labelled studies from the 1980s are the whole of the human kinetic record on testosterone propionate alone. In normal men given a single intramuscular dose of testosterone propionate labelled with three deuterium atoms, so that the injected hormone could be told apart from the men's own, the ester was gradually transferred from the injection site, held at 2 to 4 nanograms per millilitre between 3 and 36 hours, and the labelled testosterone stayed above the physiological level for 48 hours while endogenous testosterone changed little (PMID 3782423). In three men with hypogonadotropic hypogonadism the same method gave the same 48 hours (PMID 2632058).

What the hormone does once released from testosterone propionate is the largest evidence base on this site, because testosterone esters are prescription drugs with replacement trials, dose-response trials and one very large safety trial behind them. Nearly all of it was generated with the enanthate and cypionate esters, which release the same molecule over two weeks instead of two days. The estrogen, red cell, lipid and muscle findings below are therefore the testosterone record read through the propionate's timing, and the timing is the only thing the propionate changes. How injectables differ from orals as a class is on injectable vs oral steroids.

What is measured on testosterone propionate, and in whom

Testosterone propionate on its own has a small human record: two kinetic studies, a seminal plasma study, delayed-puberty series in a mixed ester, and the topical form in women. The hormone has dozens of trials. The table keeps them apart.

Read the weight column first. The propionate rows are kinetic, uncontrolled or in women and boys. The randomised rows belong to the long esters and to gel. The reason the table can still be read as one is that every row describes the same hormone; the reason it must be read carefully is that the timing rows, where the propionate differs, are the ones with the least data. That is the evidence base, and the rest of this page stays inside it.

Testosterone propionate half life: what was measured, and what was not

The testosterone propionate half life quoted on every forum, usually a figure between one and two days, does not appear in any PubMed abstract. What appears is a time course. In the labelled study in normal men, the ester was present in plasma at 2 to 4 nanograms per millilitre between 3 and 36 hours, and the testosterone released from it stayed above the physiological level for 48 hours, with the men's own testosterone changing little over that window (PMID 3782423). The follow-up in hypogonadotropic men, who make almost no testosterone of their own, gave the same 48 hours above the normal range (PMID 2632058).

The long ester gives the testosterone propionate comparison. After a single intramuscular testosterone cypionate injection in hypogonadal men, testosterone peaked on days 2 to 5 and was back to baseline by days 13 to 14, estradiol rose about threefold over days 2 to 7, and LH was suppressed from the first injection (PMID 3595893). A population model of the cypionate in 31 healthy men found the exposure a person gets depends on dose, body weight, albumin and injection interval, with suppression more severe and longer at higher doses (PMID 29436172). The propionate compresses the cypionate's two-week curve into two days, which is the whole of the testosterone propionate half life story the literature supports.

Why the testosterone propionate number matters less than the window: every effect of testosterone that follows the peak, estradiol and the red cell signal above all, follows the curve. A two-day ester produces a peak and a trough every few days rather than every two weeks, which is either an advantage, in that each trough is shallow and each peak short, or a cost, in that the axis is never given a long enough gap to matter and the injections are frequent. Which of those it is has not been measured on the propionate. The detection side has: after a single mixed-ester injection, every ester in it was detectable in blood, with detection time depending on the ester (PMID 26695486).

Testosterone propionate vs cypionate and enanthate: what differs and what does not

Testosterone propionate vs cypionate is a question about timing and nothing else, because the molecule released is identical and the receptor does not see the ester. What differs is the shape of the curve, and the shape of the curve decides three things that have been measured on the long esters: the height of the estradiol rise, the size of the hematocrit rise, and how long the axis stays down after the last injection.

The one paper that comes closest to a propionate-versus-long-ester experiment is in mice: males given short-acting testosterone propionate three times a week kept LH near control and fertility near wild-type, while males given a three-month testosterone pellet had LH almost undetectable and a longer time to pregnancy, even though both raised testosterone above control (PMID 32914138). It is a mouse, and the authors offered it as a hypothesis for preserving fertility in young hypogonadal men, not as a rule.

In men, what is measured is that a flatter testosterone curve produced less estradiol and a lower hematocrit at the same trough (PMID 34694927), which cuts the other way for a short ester injected infrequently. The long ester in its own trials is on testosterone cypionate; the same ester question for nandrolone is on NPP.

Muscle on testosterone esters: the dose-response trials

No trial has measured muscle on testosterone propionate. The muscle data for testosterone esters are the best in the field, and they were generated with the enanthate, which delivers the same hormone over two weeks. In 43 normal men randomised to placebo or a supraphysiological weekly dose with or without training for 10 weeks, testosterone without exercise increased triceps area by 424 against a loss of 81 square millimetres on placebo and quadriceps area by 607 against a loss of 131, bench press by 9 kg against a loss of 1 and squat by 16 kg against 3; testosterone with training raised fat-free mass by 6.1 kg and bench press by 22 kg (PMID 8637535).

The 2001 trial made it a dose-response. Sixty-one men aged 18 to 35 had their own production suppressed and received one of five weekly doses for 20 weeks with standardised food. Fat-free mass rose at the three highest doses by 3.4, 5.2 and 7.9 kg and the change correlated with the log of circulating testosterone; leg press strength, leg power, muscle volumes, hemoglobin and IGF-I rose with testosterone while fat mass and HDL fell with it, on a single line; sexual function, mood, cognition and PSA did not change at any dose (PMID 11701431).

What a reader of the propionate page should take from this is that the muscle effect is a property of circulating testosterone, not of the ester, and that it was measured over 10 to 20 weeks of steady exposure. A short ester reaches the same average exposure only if it is injected often enough to keep the level up, which the kinetic study answers in hours rather than days (PMID 3782423).

The lipid cost was measured on the cypionate in normal volunteers: HDL fell 21 percent after the first moderate dose, did not fall further at higher doses, and the cholesterol to HDL ratio was still elevated four weeks after the last injection (PMID 8792045). The lipid page is do steroids raise cholesterol.

Estradiol, red cells and lipids on testosterone: what follows the peak

The three effects that follow the testosterone propionate peak are the three that a two-day ester changes in timing without changing in kind. Estradiol rose about threefold over days 2 to 7 after a cypionate injection (PMID 3595893), and in 234 hypogonadal men a subcutaneous enanthate regimen designed for a lower peak-to-trough ratio produced lower estradiol and a lower hematocrit than intramuscular cypionate at the same trough testosterone, with PSA unchanged on both (PMID 34694927). The estradiol that a testosterone propionate injection produces has not been measured; the mechanism says it rises and falls with each peak.

Red cells are the best-measured of all testosterone propionate side effects, through the long esters. In 121 young and older men over 20 weeks, hemoglobin and hematocrit rose in a linear, dose-dependent way, more steeply in the older men, and the rise was not explained by erythropoietin (PMID 18160461). Four months of cypionate injections moved hematocrit from 42.7 to 46.6 percent while nasal gel did not (PMID 37126399).

In 158 hypogonadal men on depot testosterone for an average of eight years, the odds of a hematocrit above 0.50 rose with the log of trough testosterone, an odds ratio of 15.0, and with age (PMID 19903801); across randomised trials, testosterone carried a relative risk of erythrocytosis of 8.14 (PMID 29562341). The reading pages are high hematocrit on TRT and estradiol before steroids.

The safety ceiling is the largest trial ever run. In 5,246 men aged 45 to 80 with cardiovascular risk and low testosterone, testosterone gel titrated into the normal range was noninferior to placebo on death, infarction and stroke, 7.0 against 7.3 percent, but atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent on testosterone (PMID 37326322). That is replacement with a flat curve; the user end of the range is the cohort with hematocrit 0.50, HDL 0.69 mmol/l and coronary disease in 17 percent (PMID 35460300).

Testosterone propionate side effects by the evidence

Testosterone propionate side effects are testosterone side effects arriving in two-day waves. The table gives each with the strongest source that exists and says which kind of source it is; the propionate-specific rows are the ones a reader should notice, because there are few of them.

The honest summary of testosterone propionate side effects is that they are the measured side effects of testosterone, with two things specific to the ester: the exposure comes in two-day waves that have never been tested for what that does to estradiol and hematocrit in men, and the only human toxicity data on the propionate itself come from women treated topically and from seven men whose seminal plasma was sampled. The hormone is well measured; the ester is not.

Testosterone propionate bloodwork: eight markers, and when to draw them

The kinetics decide the timing more sharply for testosterone propionate than for any other ester. Testosterone is above physiological for about 48 hours after an injection (PMID 3782423), so a sample drawn on the day after an injection and one drawn just before the next measure different drugs; only the trough is comparable from month to month. The eight markers follow the trials on this page.

Timing follows the ester: draw at the trough, and draw the first panel early, since the cypionate data show estradiol and LH moving within the first week (PMID 3595893) and the propionate moves faster. The baseline set is on blood tests before steroids.

Five mistakes people make with testosterone propionate

Each of these comes from treating the ester as the drug, or the forum half-life as a measurement.

1. Quoting a half-life that no paper reports. The measured facts are a 3-to-36-hour ester window and 48 hours of supraphysiological testosterone after one injection (PMID 3782423). Plan around the window, not the number.

2. Expecting less estradiol or less hematocrit because the ester is short. Both follow the peak (PMID 3595893, PMID 34694927), and a short ester injected often produces a peak every few days. Neither has been measured on the propionate in men.

3. Reading the mouse fertility result as a human one. Short-acting propionate spared LH and fertility in mice against a long-acting pellet (PMID 32914138); the authors called it a hypothesis for young hypogonadal men, not a finding.

4. Drawing blood the day after a testosterone propionate injection. Testosterone is above physiological for 48 hours (PMID 3782423); only a trough sample is comparable, and the trough on this ester arrives within days.

5. Assuming the vial matches the label. In a drug-checking pilot, 13 percent of samples contained something other than expected, although the testosterone propionate samples were close to label (PMID 39911049). Small sample, real signal.

Verdict: the best-measured hormone on the least-measured ester

Testosterone propionate, after the papers rather than the forums, is testosterone released over two days: above physiological for 48 hours after one injection, with the ester itself in plasma from 3 to 36 hours (PMID 3782423). The hormone it releases has the dose-response trials (PMID 11701431), the muscle trial (PMID 8637535), the red cell trials (PMID 18160461, PMID 37126399), the estradiol kinetics (PMID 3595893), the lipid crossover (PMID 8792045) and the safety trial (PMID 37326322) behind it; the ester has two labelled kinetic studies, a seminal plasma study (PMID 7526746), a mouse fertility experiment (PMID 32914138) and a record of virilising women treated topically (PMID 9015039).

The testosterone propionate side effects that matter are the ones a trough panel catches in the first weeks: hematocrit, estradiol, HDL, and the axis. Everything upstream of that panel is on the PED side effects hub and on blood tests before steroids; the long ester with the trials this one lacks is testosterone cypionate.